Mantle cell lymphoma
RecruitingStudy of Venetoclax, Ibrutinib, and Rituximab or Bendamustine Combination for Patients with Untreated Mantle Cell Lymphoma Not Suitable for High-Dose Therapy
Study of Venetoclax, Ibrutinib, and Rituximab or Bendamustine Combination for Patients with Untreated Mantle Cell Lymphoma Not Suitable for High-Dose Therapy
- Disease:Mantle cell lymphoma
- Substances:BendamustineIbrutinib+2
Germany- Participants:18–64 years · 65+ years
- Substances:Bendamustine
- Sponsor:Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR












